Tolerability of inhaled N-chlorotaurine in humans: a double-blind randomized phase I clinical study | Zendy

Roland Arnitz | Zendy; Markus Stein | Zendy; P Bauer | Zendy; Barbara Lanthaler | Zendy; Herbert Jamnig | Zendy; Sabine SchollBürgi | Zendy; Katharina Stempfl-Al-Jazrawi | Zendy; Hanno Ulmer | Zendy; Bernhard Baumgartner | Zendy; Sabine Embacher | Zendy; Simon Geisler | Zendy; Johanna M. Gostner | Zendy; B Müllinger | Zendy; Beate Kälz | Zendy; Markus Nagl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tolerability of inhaled N-chlorotaurine in humans: a double-blind randomized phase I clinical study

Author(s) -

Roland Arnitz,

Markus Stein,

P Bauer,

Barbara Lanthaler,

Herbert Jamnig,

Sabine SchollBürgi,

Katharina Stempfl-Al-Jazrawi,

Hanno Ulmer,

Bernhard Baumgartner,

Sabine Embacher,

Simon Geisler,

Johanna M. Gostner,

B Müllinger,

Beate Kälz,

Markus Nagl

Publication year - 2018

Publication title -

therapeutic advances in respiratory disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.022

H-Index - 37

eISSN - 1753-4666

pISSN - 1753-4658

DOI - 10.1177/1753466618778955

Subject(s) - medicine , tolerability , double blind , anesthesia , inhalation , randomized controlled trial , clinical trial , adverse effect , placebo , alternative medicine , pathology

Inhaled NCT is well tolerated as in other applications of different body regions. Side effects are mild, topical and transitory. The study was registered prospectively in the European Clinical Trials Database of the European Medicines Agency. The EudraCT number is 2012-003700-12.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research